ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in Orlando, FL

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Endometrial Cancer
Non-Small-Cell Lung Carcinoma
Melanoma

Triple Negative Breast Cancer trials near Orlando, FL, USA:

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

in patients with unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) who received a...

Active, not recruiting
Triple Negative Breast Cancer
Drug: Sacituzumab Govitecan-hziy
Drug: Trilaciclib

Phase 2

G1 Therapeutics

Orlando, Florida, United States and 21 other locations

This trial studies ladiratuzumab vedotin (LV) with pembrolizumab in patients with triple-negative breast cancer. -...

Active, not recruiting
Triple Negative Breast Neoplasms
Drug: Pembrolizumab
Drug: ladiratuzumab vedotin

Phase 1, Phase 2

Seagen
Seagen

Orlando, Florida, United States and 49 other locations

selective inhibition of phosphoinositide-3-kinase (PI3K)-gamma, in combinations with Tecentriq and Abraxane (nab-paclitaxel) in front-line triple...

Active, not recruiting
Breast Cancer
Renal Cell Carcinoma
Drug: nab-paclitaxel
Drug: Bevacizumab

Phase 2

Infinity Pharmaceuticals
Infinity Pharmaceuticals

Orlando, Florida, United States and 23 other locations

doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC). Usually, after neoadjuvant therapy and surgery for triple ne ...

Active, not recruiting
Triple Negative Breast Cancer
Drug: Placebo
Drug: Atezolizumab

Phase 3

National Surgical Adjuvant Breast and Bowel Project Foundation (NSABP)

Orlando, Florida, United States and 216 other locations

or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after su...

Enrolling
Triple Negative Breast Cancer
Drug: Capecitabine
Drug: Sacituzumab govitecan-hziy (SG)

Phase 3

Gilead Sciences
Gilead Sciences

Orlando, Florida, United States and 131 other locations

previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do no...

Enrolling
Triple Negative Breast Cancer
PD-L1 Negative
Drug: Sacituzumab Govitecan-hziy
Drug: Paclitaxel

Phase 3

Gilead Sciences
Gilead Sciences

Orlando, Florida, United States and 508 other locations

with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors ...

Enrolling
Triple Negative Breast Cancer
PD-L1 Positive
Drug: Pembrolizumab
Drug: Paclitaxel

Phase 3

Gilead Sciences
Gilead Sciences

Orlando, Florida, United States and 508 other locations

with stage I to III TNBC with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvan...

Enrolling
Breast Cancer
Drug: Pembrolizumab
Drug: Dato-DXd

Phase 3

AstraZeneca
AstraZeneca

Orlando, Florida, United States and 359 other locations

This is a Phase 1/2a open-label, multicenter, dose escalation and dose expansion trial in which IMT-009 will be administered by the intravenous (IV)...

Enrolling
Esophageal Cancer
Non Small Cell Lung Cancer
Drug: IMT-009
Combination Product: Fruquintinib

Phase 1, Phase 2

Immunitas Therapeutics

Orlando, Florida, United States and 9 other locations

preliminary antitumor activity of NKT3447 in adult subjects with cyclin E1 (CCNE1) amplified ovarian cancer at the RDEs selected in Dose Es...

Enrolling
Triple Negative Breast Neoplasms
Platinum-resistant Ovarian Cancer
Drug: NKT3447

Phase 1

NiKang Therapeutics

Celebration, Florida, United States and 4 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems